Supplementary Figure S4 from Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S4 A) Effect of treatment with 5 nmol/L lurbinectedin for 12 hours on expression of the EWS-FLI1 target genes, BCL11B, LOX, PRKCB and STEAP1. B) Effect of treatment with 10 nmol/L lurbinectedin for 6 or 12 hours on the EWS-FLI1 gene signature of repressed targets. C) GI50 for lurbinectedin and trabectedin.
Authors: Matt L. Harlow, Nichole Maloney, Joseph Roland, Maria Jose Guillen Navarro, Matthew K. Easton, Susan M. Kitchen-Goosen, Elissa A. Boguslawski, Zachary B. Madaj, Ben K. Johnson, Megan J. Bowman, Maurizio D'Incalci, Mary E. Winn, Lisa Turner, Galen Hostetter, Carlos María Galmarini, Pablo M. Aviles, Patrick J. Grohar
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361877797